A Phase 4 interventional study of Hectorol (doxercalciferol injection) and Zemplar (Paricalcitol injection) in Secondary Hyperparathyroidism, sponsored by Genzyme, a Sanofi Company. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-05.
Sponsored by Genzyme, a Sanofi Company · Phase 4, Interventional, and Treatment
This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).
305 studies on the registry are indexed under Hyperparathyroidism; 23 are open to participants now.
This study's planned enrollment of 12 is below the median of 58 across 203 interventional studies indexed under Hyperparathyroidism.
Browse Hyperparathyroidism studies →Genzyme, a Sanofi Company is the lead sponsor of 303 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 19 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Pharmacokinetic Study
Time frame: 44 hour interval
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genzyme, a Sanofi Company